<p>Patients were taken off of conventional therapies from two weeks prior to and 30 days after treatment with <sup>131</sup>I-CLR1404. After treatment with <sup>131</sup>I-CLR1404, patients underwent nuclear medicine procedures for 14 days and were followed for safety for 42 days.</p
<p>Consort Flow Diagram for the KTS-2-2010 study, with enrollment, allocation to induction and maint...
<p>184 subjects were assigned to receive lifestyle intervention alone (n = 62), lifestyle interventi...
Aim: The goal of this study was to estimate the cumulative activity of (131)I to be administered to ...
Background: 131 I-meta-iodobenzylguanidine (131 I-MIBG) has been in therapeutic use since 1980s. New...
Introduction: 131I-CLR1404 is a small molecule that combines a tumor-targeting moiety with a therape...
<div><p>Introduction</p><p><sup>131</sup>I-CLR1404 is a small molecule that combines a tumor-targeti...
Patients who were randomly assigned and received the intended treatment were analyzed for the outcom...
textabstractOBJECTIVES: To determine the long term outcome after intracoronary beta radiation therap...
BACKGROUND: (131)I-meta-iodobenzylguanidine ((131)I-MIBG) has been in therapeutic use since 1980s. N...
A methodology was developed determining patient releasability after radioimmunotherapy with tositumo...
Objectives: To determine the long term outcome after intracoronary β radiation therapy (IRT). Settin...
<p>The patients who had at least one follow-up visit remained including in the study. </p
<p>CONSORT diagram of Phase II trial of radioembolization followed by sequential sorafenib in patien...
UC = usual care. * One patient received prophylactic antibiotics before protocol amendment. ** All p...
<p>A consort diagram for the 69 patients who participated in the study is shown.</p
<p>Consort Flow Diagram for the KTS-2-2010 study, with enrollment, allocation to induction and maint...
<p>184 subjects were assigned to receive lifestyle intervention alone (n = 62), lifestyle interventi...
Aim: The goal of this study was to estimate the cumulative activity of (131)I to be administered to ...
Background: 131 I-meta-iodobenzylguanidine (131 I-MIBG) has been in therapeutic use since 1980s. New...
Introduction: 131I-CLR1404 is a small molecule that combines a tumor-targeting moiety with a therape...
<div><p>Introduction</p><p><sup>131</sup>I-CLR1404 is a small molecule that combines a tumor-targeti...
Patients who were randomly assigned and received the intended treatment were analyzed for the outcom...
textabstractOBJECTIVES: To determine the long term outcome after intracoronary beta radiation therap...
BACKGROUND: (131)I-meta-iodobenzylguanidine ((131)I-MIBG) has been in therapeutic use since 1980s. N...
A methodology was developed determining patient releasability after radioimmunotherapy with tositumo...
Objectives: To determine the long term outcome after intracoronary β radiation therapy (IRT). Settin...
<p>The patients who had at least one follow-up visit remained including in the study. </p
<p>CONSORT diagram of Phase II trial of radioembolization followed by sequential sorafenib in patien...
UC = usual care. * One patient received prophylactic antibiotics before protocol amendment. ** All p...
<p>A consort diagram for the 69 patients who participated in the study is shown.</p
<p>Consort Flow Diagram for the KTS-2-2010 study, with enrollment, allocation to induction and maint...
<p>184 subjects were assigned to receive lifestyle intervention alone (n = 62), lifestyle interventi...
Aim: The goal of this study was to estimate the cumulative activity of (131)I to be administered to ...